Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Aas, Kirsti; Fosså, Sophie D.; Kvåle, Rune; Møller, Bjørn; Myklebust, Tor Åge; Vlatkovic, Ljiljana; Müller, Stig; Berge, Viktor

doi:10.1007/s00345-018-2570-6

Cited by 15 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nineteen studies were finally included in the present systematic review [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. Table 1 summarizes the studies and their main findings.…”

Section: Search Resultsmentioning

confidence: 99%

“…Two studies found no significant impact of treatment delay on survival outcomes (PCSM and MFS) [22,25]. Aas et al reported no association between RP-interval and PCSM in the intermediate-or high-risk groups in a study of 5163 patients with time from diagnosis to treatment stratified by intervals: ≤ 60, 61-90, 91-120 and 121-180 days [25].…”

Section: Survival Outcomesmentioning

confidence: 99%

“…We found a significant heterogeneity across the studies in terms of delayed RP definitions. Most of the studies used 3-month intervals between diagnosis and RP [9,10,[20][21][22]; three studies used 2-month intervals [23][24][25]. Diamand [14][15][16].…”

Section: Definition Of Delaymentioning

confidence: 99%

“…Two studies reported data on survival outcomes, particularly on prostate cancer-specific mortality (PCSM) [25] and metastasis-free survival (MFS) [22]. Nine studies reported data on biochemical recurrence (BCR) [9,13,15,[21][22][23][24]26].…”

Section: Definition Of Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review

et al. 2021

View full text Add to dashboard Cite

Purpose To summarize the available evidence on the survival and pathologic outcomes after deferred radical prostatectomy (RP) in men with intermediate- and high-risk prostate cancer (PCa). Methods The PubMed database and Web of Science were searched in November 2020 according to the PRISMA statement. Studies were deemed eligible if they reported the survival and pathologic outcomes of patients treated with deferred RP for intermediate- and high-risk PCa compared to the control group including those patients treated with RP without delay. Results Overall, nineteen studies met our eligibility criteria. We found a significant heterogeneity across the studies in terms of definitions for delay and outcomes, as well as in patients’ baseline clinicopathologic features. According to the currently available literature, deferred RP does not seem to affect oncological survival outcomes, such as prostate cancer-specific mortality and metastasis-free survival, in patients with intermediate- or high-risk PCa. However, the impact of deferred RP on biochemical recurrence rates remains controversial. There is no clear association of deferring RP with any of the features of aggressive disease such as pathologic upgrading, upstaging, positive surgical margins, extracapsular extension, seminal vesicle invasion, and lymph node invasion. Deferred RP was not associated with the need for secondary treatments. Conclusions Owing to the different definitions of a delayed RP, it is hard to make a consensus regarding the safe delay time. However, the current data suggest that deferring RP in patients with intermediate- and high-risk PCa for at least around 3 months is generally safe, as it does not lead to adverse pathologic outcomes, biochemical recurrence, the need for secondary therapy, or worse oncological survival outcomes.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Survival Outcomesmentioning

confidence: 99%

Section: Definition Of Delaymentioning

confidence: 99%

Section: Definition Of Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…On one hand, the fact that we only included patients following radical prostatectomy is a very rigorous patient selection, which allows excellent comparability and precise factor evaluation, but, on the other hand, this might cause a selection bias and does not allow us to make statements about patients with advanced tumor stages and inoperable settings. Furthermore, we neglected time between diagnosis and RP, since recently published studies did not show an impact on oncological outcomes [22,23]. Fig.…”

Section: Discussionmentioning

confidence: 99%

The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy

et al. 2020

View full text Add to dashboard Cite

Purpose To determine whether fatal family history (FFH) or mode of inheritance in prostate cancer (PCa) has an impact on long-term outcomes following radical prostatectomy (RP). Methods 1076 PCa patients after RP with at least one deceased first-degree relative with PCa were included and stratified by FFH (four subgroups: fraternal, paternal, multiple, and none) and by mode of inheritance (two subgroups: male to male, non-male to male). We compared clinicopathological characteristics between subgroups with Fisher's exact or Chi-square tests. Biochemical recurrence-free survival (BRFS) and cancer-specific survival (CSS) were analyzed using the method of Kaplan and Meier. Simple and multiple Cox regression with backward elimination were performed to select prognostic factors for BRFS and CSS. Results Median age at surgery was 63.3 (range 35.9-79.4) years. The overall Kaplan-Meier estimated BRFS rate at 10 and 15 years was 65.6% and 57.0%, respectively. The overall Kaplan-Meier estimated CSS rate at 10 and 15 years was 98.1% and 95.7%, respectively. Neither FFH nor mode of inheritance were factors associated with worse BRFS. However, in multiple Cox regression, paternal FFH was an important prognostic factor for a better CSS (HR 0.19, CI 0.05-0.71, p = 0.014) compared to non-FFH. Conclusion FFH and mode of inheritance do not seem to be prognostic factors of worse long-term outcomes following RP. Rather, a paternal FFH was associated with a better CSS; however, the reasons remain unclear. Nevertheless, patients after RP and FFH could be reassured that their own PCa diagnosis is not associated with a worse long-term outcome.

show abstract

Impact of surgical wait times during summer months on the oncological outcomes following robotic-assisted radical prostatectomy: 10 years’ experience from a large Canadian academic center

et al. 2020

View full text Add to dashboard Cite

Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Cited by 15 publications

References 27 publications

Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review

Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review

The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy

Impact of surgical wait times during summer months on the oncological outcomes following robotic-assisted radical prostatectomy: 10 years’ experience from a large Canadian academic center

Contact Info

Product

Resources

About